Prostate cancer is the most common malignancy among men in Western countries and second most cause of cancer-related death. The three unmet needs in treatment of prostate cancer are 1) how to identify patients who needs active treatment, 2) how to choose the best possible treatment, and 3) how to improve treatment for the aggressive disease form. The long non-coding RNAs (lncRNAs) are implicated in several diseases, including prostate cancer. However, their functions and significance are poorly understood. Here, we will identify lncRNAs that are altered specifically in aggressive prostate cancer. We will study how they function in prostate cancer cells as well as their significance as diagnostic marker. We will utilize the unique sample biorepository we have collected and our skills in genomics. The aim is to find out whether lncRNAs could function as biomarkers or drug targets. The study will be conducted in Tampere University.

2024

2028